Mapping the active site of CD59

Journal of Experimental Medicine

Volumn 185, Issue 4, 1997, Pages 745-753

  Yu, Jinghua ^a   Abagyan, Ruben ^b   Dong, Shanghong ^a,c   Gilbert, Alexander ^a   Nussenzweig, Victor ^a   Tomlinson, Stephen ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CHIMERIC PROTEIN; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ANIMAL CELL; ARTICLE; AUTOIMMUNITY; CHO CELL; CONTROLLED STUDY; FLOW CYTOMETRY; INFLAMMATION; MOLECULAR MODEL; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD59; ANTIGENS, SURFACE; BINDING SITES; CARBOHYDRATE METABOLISM; CHO CELLS; CRICETINAE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0031035061     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.4.745     Document Type: Article

References (43)

1. Fletcher, C.M., R.A. Harrison, P.J. Lachmann, and D. Neuhaus. 1994. Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure. 2: 185-199.
2. Kieffer, B., P.C. Driscoll, I.D. Campbell, A.C. Willis, P.A. van der Merwe, and S.J. Davis. 1994. Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins. Biochem. 33:4471-4482.
3. Rollins, S.A., J.I. Zhao, H. Ninomiya, and P.J. Sims. 1991. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J. Immunol. 146: 2345-2351.
4. Ninomiya, H., and P.J. Sims. 1992. The human complement regulatory protein CD59 binds to the alpha chain of C8 and to the "b" domain of C9. J. Biol. Chem. 267:13675-13680.
5. Rollins, S.A., and P.J. Sims. 1990. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation ot C9 into membrane C5b-9. J. Immunol. 144:3478-3483.
6. Meri, S., B.P. Morgan, A. Davies, R.H. Daniels, M.G. Olavesen, H. Waldemann, and P.J. Lachmann. 1990. Human protectin (CD59), an 18-20 kD complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunol. 72:1-9.
7. Weisman, H.F., T. Bartow, M.K. Leppo, H.C. Marsh, G.R. Carson, M.F. Consino, M.P. Boyle, K.H. Roux, M.L. Weisfeldt, and D.T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor ot complement suppressing post-ischemic myocardial inflammation and necrosis. Science (Wash. DC). 249:146-151.
8. Moran, P., H. Beasly, A. Gorrel, E. Martin, P. Gribling, H. Fuchs, N. Gillet, L.E. Burton, and I.W. Caras. 1992. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J. Immunol. 149:1736-1743.
9. Christiansen, D., J. Milland, B.R. Thorley, I.F. McKenzie, and B.E. Loveland. 1996. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur. J. Immunol. 26:578-585.
10. Sugita, Y., K. Ito, K. Shiozuka, H. Gushima, M. Tomita, and Y. Masuho. 1994. Recombinant soluble CD59 inhibits reactive haemolysis with complement. Immunol. 82:34-41.
11. Matis, L.A., and S.A. Rollins. 1995. Complement-specific antibodies: Designing novel anti-inflammatories. Nat. Med. 1: 839-842.
12. Parker, W., D. Bruno, and J.L. Platt. 1995. Xenoreactive natural antibodies in the world of natural antibodies: typical or unique? Transplant Immunol. 3:181-191.
13. McCurry, K.R., D.L. Kooyman, C.G. Alvarado, A.H. Cotterell, M.J. Martin, J.S. Logan, and J.L. Platt. 1995. Human complement regulatory proteins protect swine-to-primate cardiac xenographs from humoral injury. Nature Med. 1:423-127.
14. Roush, W. 1995. New ways to avoid organ rejection buoys hopes. Science (Wash. DC). 270:234-235.
15. Fodor, W.L., B.L. Williams, L.A. Matis, J.A. Madri, S.A. Rollins, J.W. Knight, W. Velander, and S.P. Squinto. 1994. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ transplantation. Proc. Natl. Acad. Sci. USA. 91:11153-11157.
16. Byrne, G.W., K.R. McCurry, D. Kagan, C. Quinn, M.J. Martin, J.L. Platt, and J.S. Logan. 1995. Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice. Transplantation. 60:1149-1156.
17. Ploug, M., and V. Ellis. 1994. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 349:163-168.
18. LeClair, K.P, R.G. Palfree, P.M. Flood, U. Haemmerling, and A. Bothwell. 1986. Isolation of a murine Ly-6 cDNA reveals a new multigene family. EMBO (Eur. Mol. Biol. Organ.) J. 5:3227-3234.
19. Harlow, E., and D. Lane. 1988. Antibodies. A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 53-138.
20. Diaz, R., L. Mayorga, and P. Stahl. 1988. In vitro fusion of endosomes following receptor-mediated endocytosis. J. Biol. Chem. 263:6093-6100.
21. Okada, R., N. Okada, T. Fujita, and H. Okada. 1990. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. J. Immunol. 144:1823-1827.
22. Bodian, D.L., S.J. Davies, B.P. Morgan, and N.K. Rushmere. 1997. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J. Exp. Med. In Press.
23. Nardin, E.H., V. Nussenzweig, and R.S. Nussenzweig. 1982. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156:20-30.
24. Vallejo, A.N., R.J. Pogulis, and L.R. Pease. 1995. PCR Primer. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 603-612.
25. Totrov, M.M., and R.A. Abagyan. 1996. The contour-buildup algorithm to calculate the analytical molecular surface. J. Struct. Biol. 116:138-143.
26. Molsoft, L.C.C. 1996. ICM software manual version 2.5.
27. Abagyan, R.A., and M.M. Totrov. 1994. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 235:983-1002.
28. Nakano, Y., K. Noda, T. Endo, A. Kobata, and M. Tomita. 1994. Structural study on the glycosyl-phosphatidylinositol anchor and the asparagine-linked sugar chain of a soluble form of CD59 in human urine. Arch. Biochem. Biophys. 311: 117-126.
29. Ninomiya, H., B.H. Stewart, S.A. Rollins, J. Zhao, A.L. Bothwell, and P.J. Sims. 1992. Contribution of N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity. J. Biol. Chem. 267:8404-8410.
30. Akami, T., K. Arakawa, M. Okamoto, I. Fujiwara, I. Nakai, M. Mitsuo, R. Sawada, M. Naruto, and T. Oka. 1994. Enhancement of the complement regulatory function of CD59 by site-directed mutagenesis at the N-glycosylation site. Transp. Proc. 26:1256-1258.
31. Hahn, W.C., E. Menu, A.L. Bothwell, P.J. Sims, and B.E. Bierer. 1992. Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science (Wash. DC). 256:1805-1807.
32. Deckert, M., J. Kubar, D. Zoccola, G. Bernard-Pomier, P. Angelisova, V. Horejsi, and A. Bernard. 1992. CD59 molecule: a second ligand for CD2 in T cell adhesion. Eur. J. Immunol. 22:2943-2947.
33. Menu, E., B.C. Tsai, A.L.M. Bothwell, P.J. Sims, and B.E. Bierer. 1994. CD59 costimulation of T cell activation. J. Immunol. 153:2444-2456.
34. Marshall, P.M., A. Hasegawa, E.A. Davidson, V. Nussenzweig, and M. Whitlow. 1996. Interaction between complement proteins C5b-7 and erythrocyte membrane sialic acid. J. Exp. Med. 184:1225-1232.
35. Complement in Health and Disease. 1993. K. Whaley, M. Loos, and J.M. Weiter, editors. Kluwer Academic Publishers, Dordrecht, Germany.
36. Verlinde, C.L., and W.G. Hol. 1994. Structure-based drug design:progress, results and challenges. Structure. 2:577-587.
37. Hakulinen, J., and S. Meri. 1994. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab. Invest. 71: 820-827.
38. Junnikkala, S., J. Hakulinen, and S. Meri. 1994. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur. J. Immunol. 24:611-615.
39. Sugita, Y., T. Tobe, E. Oda, M. Tomita, K. Yasukawa, N. Yamaji, T. Takemoto, K. Furuichi, M. Takayama, and S. Yano. 1989. Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. J. Biochem. 106:555-557.
40. Fodor, W.L., S.A. Rollins, S. Bianco-Caron, W.V. Burton, E.R. Guilmette, R.P. Rother, G.B. Zavoico, and S.P. Squinto. 1995. Primate terminal complement inhibitor homologues of human CD59. Immunogen. 41:51.
41. Rother, R.P., S.A. Rollins, J. Menone, W.L. Fodor, and S.P. Squinto. 1993. Marmoset and Owl monkey, (unpublished) Entrez report: ATRCD59H, accession L22860.
42. Rushmere, N.K., R.A. Harrison, C.W. van der Berg, and B.P. Morgan. 1994. Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem. J. 304:595-601.
43. Albrecht, J.C., J. Nicholas, K.R. Cameron, C. Newman, B. Fleckenstein, and R.W. Honess. 1992. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. Virol. 190:527-530.